Osmotica Pharmaceuticals is a holding company. Through its subsidiaries, Co. is focused on the development and commercialization of products that target markets with underserved patient populations. Co.'s promoted products include: M-72, which is for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 to 65; Arbaclofen ER, which is for the treatment of multiple sclerosis spasticity; and OS870, which is for the treatment of neurodegenerative disorder. Co.'s non-promoted products include Methylphenidate ER, which is for the treatment of ADHD and Venlafaxine ER tablets, which is for the treatment of depressive disorder and social anxiety disorder. The OSMT average annual return since 2018 is shown above.
The Average Annual Return on the OSMT average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OSMT average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OSMT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|